- Home
- CARS vs RLAY Comparison
CARS vs RLAY Comparison
Compare CARS & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CARS
- RLAY
- Stock Information
- Founded
- CARS 1998
- RLAY 2015
- Country
- CARS United States
- RLAY United States
- Employees
- CARS N/A
- RLAY N/A
- Industry
- CARS Motor Vehicles
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CARS Consumer Discretionary
- RLAY Health Care
- Exchange
- CARS Nasdaq
- RLAY Nasdaq
- Market Cap
- CARS 741.3M
- RLAY 620.4M
- IPO Year
- CARS 2017
- RLAY 2020
- Fundamental
- Price
- CARS $11.38
- RLAY $2.47
- Analyst Decision
- CARS Buy
- RLAY Strong Buy
- Analyst Count
- CARS 5
- RLAY 10
- Target Price
- CARS $19.90
- RLAY $19.33
- AVG Volume (30 Days)
- CARS 938.6K
- RLAY 2.6M
- Earning Date
- CARS 05-08-2025
- RLAY 05-01-2025
- Dividend Yield
- CARS N/A
- RLAY N/A
- EPS Growth
- CARS N/A
- RLAY N/A
- EPS
- CARS 0.72
- RLAY N/A
- Revenue
- CARS $719,152,000.00
- RLAY $10,007,000.00
- Revenue This Year
- CARS $5.81
- RLAY N/A
- Revenue Next Year
- CARS $4.69
- RLAY $420.18
- P/E Ratio
- CARS $15.78
- RLAY N/A
- Revenue Growth
- CARS 4.35
- RLAY N/A
- 52 Week Low
- CARS $10.80
- RLAY $2.38
- 52 Week High
- CARS $21.24
- RLAY $10.72
- Technical
- Relative Strength Index (RSI)
- CARS 36.25
- RLAY 29.80
- Support Level
- CARS $10.87
- RLAY $3.05
- Resistance Level
- CARS $12.51
- RLAY $3.08
- Average True Range (ATR)
- CARS 0.50
- RLAY 0.24
- MACD
- CARS 0.17
- RLAY -0.05
- Stochastic Oscillator
- CARS 33.63
- RLAY 6.19
About CARS Cars.com Inc.
Cars.com Inc is an online destination for buying and selling new and used vehicles. It is an audience-driven technology company empowering the automotive industry. The company brands include Dealer Inspire, DealerRater, FUEL, Accu-Trade, PickupTrucks.com, CreditIQ, and NewCars.com., websites directed towards different consumer segments.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).